Prevalence and prognostic significance of heart failure with preserved ejection fraction in systemic sclerosis
| Autor: | Mário Santos, Marta Fontes Oliveira, Ana Leonor Rei, Isabel Almeida, Maria Isilda Oliveira |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Population 030204 cardiovascular system & hematology Left ventricular hypertrophy Ventricular Function Left 03 medical and health sciences 0302 clinical medicine Internal medicine Natriuretic Peptide Brain Prevalence Left atrial enlargement medicine Humans education Heart Failure 030203 arthritis & rheumatology education.field_of_study Scleroderma Systemic business.industry Interstitial lung disease Stroke Volume Atrial fibrillation Prognosis medicine.disease Peptide Fragments Heart failure Cardiology Molecular Medicine Cardiology and Cardiovascular Medicine Heart failure with preserved ejection fraction business Complication Biomarkers |
| Zdroj: | Future Cardiology. 18:17-25 |
| ISSN: | 1744-8298 1479-6678 |
| DOI: | 10.2217/fca-2020-0238 |
| Popis: | Aim: Heart failure with preserved ejection fraction (HFpEF) is a clinically relevant complication of systemic sclerosis (SSc). We aimed to examine the prevalence, correlates and prognostic significance of HFpEF in an SSc population. Materials & methods: HFpEF was defined by the presence of exertional dyspnoea, abnormal cardiac structure (left ventricular hypertrophy or left atrial enlargement) and NT-proBN (>125 pg/ml). Results: Of the 155 studied patients, 27% had HFpEF criteria. These patients were older, had more cardiovascular risk factors, and were more likely to have atrial fibrillation or interstitial lung disease. Conclusion: Over a median follow-up of 9 years, SSc patients with HFpEF had a 3.4-fold increased risk of dying (HR: 3.37, 95% CI: 1.21–9.31), although this association has lost statistical significance after adjusting for age. On the contrary, NT-proBNP was an independent predictor of a worse prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|